Key Points for Decision Makers {#FPar1}
==============================

There is large uncertainty in the clinical pathway for chronic idiopathic constipation.Multiple indirect comparisons are possible between treatments using different endpoints.Lubiprostone appears to be a cost-effective option at UK list price compared with prucalopride and immediate referral.

Introduction {#Sec1}
============

Chronic idiopathic constipation (CIC) is a common disorder characterized as constipation over an extended time period with no known cause. The most widely accepted definition of CIC uses the Rome IV diagnostic criteria \[[@CR1]\], which requires that patients fulfil certain symptom criteria relating to their bowel habit, including the relative frequency of defecations \[[@CR2]\]. It is distinct from irritable bowel syndrome in that abdominal pain is not the key feature. CIC has a severe impact on the health and wellbeing of patients, with the size of the effect comparable to that of musculoskeletal diseases, diabetes, heart disease and depression \[[@CR3], [@CR4]\].

As disease onset is slow \[[@CR5]\] and diagnosis is often delayed because patients self-medicate, the exact prevalence of CIC is unknown \[[@CR6]\]. One estimate suggests that approximately 570,000 adult patients in England and Wales have general practitioner (GP)-diagnosed constipation \[[@CR6]\]. The diagnosis involves taking a detailed history, excluding secondary causes, and investigations as appropriate. Depending on the patient's symptoms and the physician, investigation may include blood tests, colonoscopy, transit studies and anorectal physiology.

Lubiprostone (Amitiza^®^, Takeda UK Ltd) is a locally acting chloride channel-2 activator. The safety and efficacy of lubiprostone in CIC was studied in three phase III randomized controlled trials (RCTs) (*n* = 603) \[[@CR7]--[@CR9]\]. These studies demonstrated that lubiprostone significantly increased spontaneous bowel movements (SBMs) and other clinically relevant endpoints compared with placebo. Evidence of sustained efficacy is also available from four long-term open-label studies \[[@CR9]--[@CR12]\].

In the UK, the National Institute for Health and Care Excellence (NICE) seeks to review the clinical and cost-effectiveness evidence of new medicines, aiming to maximize the health (defined in terms of quality-adjusted life-years \[QALYs\]) of the population within a fixed healthcare budget. In August 2013, NICE elected to assess lubiprostone as a treatment for CIC in a single technology appraisal. The scope of the appraisal was to compare lubiprostone with bulk-forming, osmotic and stimulant laxatives and prucalopride in a population of adults with CIC, when response to diet and other non-pharmacological measures are inappropriate \[[@CR13]\]. The cost-effectiveness results considered in developing the final appraisal determination are reported elsewhere \[[@CR14]\]. In this study, we describe the economic model and inputs, update the costs to year 2016 values and report results of a less conservative analysis (using most likely estimates for parameters according to expert validation) in which we considered a longer time horizon, such that patients were in comparable states at the end of the model, and an additional comparator to reflect the clinical pathway in the UK.

Methods {#Sec2}
=======

Model Structure {#Sec3}
---------------

There is no consensus pathway for the management of CIC, so we conducted advisory boards with clinical experts. The five experts involved in the process were clinicians currently working in the UK NHS in a variety of settings, including one GP, three secondary care consultant gastroenterologists and one gastrointestinal medicine expert. Their views were collected in a questionnaire prior to meeting and then through discussion to reach unanimous agreement. Their unanimous view was that lubiprostone would be used when at least two laxatives had failed, because many inexpensive laxatives would have been used before this. The objective of treatment at this stage is to treat patient's symptoms and avoid unnecessary referrals to investigations and invasive procedures.

We constructed a cohort state-transition model in Microsoft^®^ Excel. State-transition models are appropriate where a disease can be categorized into mutually exclusive and collectively exhaustive states and where any individuals in the same health state have the same quality of life and the same healthcare resource use. The health states were chosen to reflect the treatment pathway and whether a person had resolved or unresolved CIC. The health states in the model were as follows:'treatment', during which patients receive lubiprostone, placebo or prucalopride,'investigations/invasive procedures', in which all patients visit a gastroenterologist, 95% have a colonoscopy, and 61% undergo invasive procedures (of which 98.9% are biofeedback, 1.0% are sacral neuromodulation, 0.1% are stoma surgery) \[[@CR15]\],'resolved', which patients enter if the invasive procedures are curative (95% probability for sacral neuromodulation and stoma surgery, 62% for biofeedback) \[[@CR16]\], and'unresolved', which patients enter if they have been treated with lubiprostone or prucalopride and invasive procedures are either not received or not curative.

Figure [1](#Fig1){ref-type="fig"} shows the structure of the economic model. We used a cycle length of 2 weeks---the duration of the initial trial period of lubiprostone.Fig. 1Economic model structure. The dashed line indicates transition is considered in the scenario analysis only and not in the base case

The perspective of the model was NHS and personal social services. Costs and QALYs were discounted annually at 3.5% \[[@CR17]\]. The NICE reference case for economic evaluation stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared. For a comparison against another active drug (prucalopride), a short time horizon is sufficient. However, for comparison with immediate referral, a longer time horizon is required to capture all relevant differences and ensure patients are in comparable health states at the end of the model period. We therefore present results for a 1-year time horizon (as considered by NICE) and for a 10-year time horizon.

Comparators {#Sec4}
-----------

We considered prucalopride, placebo and immediate referral to secondary care as comparators. Prucalopride is arguably the most relevant comparator, as it is licensed and recommended in the same indication \[[@CR18]\]. However, questions remain over what the most appropriate comparator is where prucalopride is not used. In the NICE appraisal, placebo was considered as a comparator and was assumed to be representative of standard laxative treatment (which patients received alongside placebo in the trial). Since referrals to investigations and invasive procedures are being considered in this indication, we included immediate referral to secondary care as an additional comparator.

Clinical Inputs {#Sec5}
---------------

On the advice of clinicians, the economic model incorporated a treatment continuation rule that determined whether or not a patient had adequately responded and should continue treatment beyond the initial period.

The initial period for lubiprostone and placebo is 2 weeks, based on the UK summary of product characteristics for lubiprostone \[[@CR19]\]. In order to continue treatment after the initial trial period, patients must have had three or more SBMs with no use of rescue medication during week 2; for placebo, this was 53.5% of patients based on a meta-analysis of the RCTs. The relative risk of response at week 2 for lubiprostone compared with placebo was 1.30 \[[@CR20]\].

The initial trial period for prucalopride is 4 weeks before response is assessed \[[@CR21], [@CR22]\]. When response at week 4 is defined as having three or more SBMs with no use of rescue medication during week 4, a total of 50.0% of patients receiving placebo responded and the relative risk of response at week 4 for lubiprostone compared with placebo was 1.38. The probability of response at week 4 for prucalopride was calculated by multiplying the placebo response by the relative risk for lubiprostone versus placebo and dividing by the relative risk for lubiprostone versus prucalopride.

The relative risk for lubiprostone versus prucalopride was calculated from indirect comparisons. The RCTs for lubiprostone and prucalopride had different primary endpoints, and the prucalopride trial did not include the definition of response used in the lubiprostone analysis. Therefore, the relative effectiveness of lubiprostone versus prucalopride was estimated from other outcomes. Several outcomes were common to both lubiprostone and prucalopride trials, which permitted indirect comparisons to be performed for seven different measures (Table [1](#Tab1){ref-type="table"}). The indirect comparisons used the Bucher approach \[[@CR23]\], and methods are described elsewhere \[[@CR20], [@CR23]\]. The base case used the 'change in SBM from baseline' (the primary endpoint of the lubiprostone studies), which showed numerical superiority for lubiprostone over prucalopride without reaching statistical significance. The relative effectiveness of prucalopride compared with lubiprostone was applied in the model to the definition of response.Table 1Relative risks derived from indirect comparisons of lubiprostone versus prucaloprideOutcomeLubiprostone vs. prucaloprideFavoursRR (95% CI)Change in SBM from baseline1.12 (0.77--1.64)LubiprostonePercentage of patients achieving an average increase in SBM of ≥ 1 over weeks 1--41.04 (0.84--1.28)PrucaloprideSBMs rated as 'normal'0.73 (0.63--0.85)Prucalopride\*SBMs rated as 'hard' or 'very hard'0.78 (0.60--1.01)LubiprostoneSBMs with no straining1.27 (0.79--2.03)LubiprostoneSBMs with severe/very severe straining0.67 (0.48--0.92)Lubiprostone\*Mean change in SCBM from baseline over weeks 1--42.60 (0.59--4.61)LubiprostoneAssume same efficacy1.00Neither*CI* confidence interval, *RR* relative risk, *SBM* spontaneous bowel movement, *SCBM* spontaneous complete bowel movement\**p* \< 0.05

To incorporate treatment discontinuation beyond the stopping rule at week 2 or 4, parametric curves were fitted to discontinuation data beyond week 2 from the long-term open-label lubiprostone studies combined with long-term US prescription data \[[@CR12]\]. The rate of discontinuation after implementation of the treatment continuation rule was assumed to be the same for prucalopride as for lubiprostone because the reasons for discontinuation would be similar. The best-fitting curve, according to visual inspection, Akaike information criterion and Bayesian inference criterion, was the log-logistic, with scale parameter 4.26 and shape parameter 0.24. For placebo, the base-case scenario considered that patients discontinued treatment using the same data, and a scenario analysis considered that placebo had no lasting effect after the initial 2-week period, with all patients then discontinuing to be moved to investigative treatment.

Patients who responded to treatment remained on treatment until they discontinued. After non-response (at week 2 for lubiprostone or week 4 for prucalopride) or discontinuation, patients moved immediately into the 'investigations/invasive procedures' health state, where they remained for one cycle. A proportion of patients moved from 'investigations/invasive procedures' into 'resolved' and the remainder into 'unresolved', where they remained until the end of the model time horizon.

All-cause mortality was included in the model, using age- and sex-specific mortality data from life tables for England and Wales \[[@CR24]\]. In the base case, it was assumed that CIC affected only quality of life and not survival. There is some evidence that constipation may be linked to increased mortality \[[@CR25]--[@CR28]\], so a scenario was considered using a hazard ratio for mortality of 1.19 for unresolved versus resolved CIC \[[@CR29]\].

Health-Related Quality of Life {#Sec6}
------------------------------

A large (*n* = 1200) study in CIC enrolling patients in the USA and Canada reported EuroQol Five-Dimension (EQ-5D) utility scores at baseline (0.83) and for responders (0.90) and non-responders (0.86) \[[@CR30]\]. The model assumed that the utility in the initial trial period for placebo, lubiprostone and prucalopride was an average of responder and non-responder utilities, weighted for the proportion of responders for each treatment. Beyond the initial period, the utility value for patients who continued on treatment was that of a responder, since they had, by definition, responded to treatment. Patients undergoing invasive procedures were non-responders to treatment and so had the utility value for a non-responder. Following invasive procedures, patients who were cured had the utility value for a responder. Those whose condition remained unresolved were assumed to have a poorer quality of life than those at an earlier stage in the pathway and were not assumed to receive active treatment, so had the utility value from baseline (Table [2](#Tab2){ref-type="table"}).Table 2Health state costs and utilitiesCostsNumber of units per 2-week cycleInvestigations/invasive proceduresSourcesItemUnit cost (£)SourceOn treatmentResolvedUnresolvedGP home visit100^a^PSSRU 2016 \[[@CR36]\]0.01610.00920.03450.0345Guest et al. \[[@CR34]\] 2008GP telephone consultations140.03870.01760.05520.0552GP clinic visit310.47340.15490.50440.5044Laboratory test3NHS reference costs 2015--16 \[[@CR35]\]0.04480.02220.06060.0606Accident and emergency visit1150.00150.00080.00230.0023Hospital outpatient appointment (follow-up)1320.01340.00920.01230.0123Hospital outpatient appointment (first attendance)1651Expert opinionColonoscopy3710.95Stoma surgery1310PRU NICE costing template, inflated to 2015--16 \[[@CR43]\]0.001PRU NICE costing template \[[@CR43]\]Sacral neuromodulation96600.01Biofeedback792^b^0.989Total cost£18.97£7.39£22.00£1056.74Utility valueHuang et al. \[[@CR30]\] 2012Before stopping rule: PL 0.88; LUB 0.89; PRU 0.88. After stopping rule: 0.900.900.830.86Huang et al. \[[@CR30]\] 2012*GP* general practitioner, *LUB* lubiprostone, *NICE* UK National Institute for Health and Care Excellence, *PL* placebo, *PRU* prucalopride, *PSSRU* Personal Social Services Research Unit^a^Assumed half hour GP time^b^Six outpatient follow-up appointments

Costs {#Sec7}
-----

All patients in the economic model receiving lubiprostone, placebo or prucalopride incurred the cost of the initial treatment period before response was assessed. Lubiprostone (dosed 24 µg twice daily) was available in a 2-week starter pack (28 tablets), costing £29.68 \[[@CR31]\]. Beyond this initial period, patients who met the treatment continuation rule continued to receive lubiprostone in a larger pack of 56 tablets (4 weeks), costing £53.48 \[[@CR31]\]. Prucalopride (dosed 2 mg once daily in adults and 1 mg once daily in the elderly), is available only in 4-week (28 tablets) packs costing £59.52 (2 mg) and £38.69 (1 mg) \[[@CR31]\]. In the pivotal lubiprostone trials, 11.3% of patients were aged \> 65 years \[[@CR7]--[@CR9]\]. To create an unbiased comparison, this percentage of patients aged \> 65 years from the lubiprostone trials was used, which led to a weighted cost of £57.17 for prucalopride. All patients receiving prucalopride incurred this cost before response was assessed (at 4 weeks).

In the NICE submission, placebo was assumed to have no cost. However, since placebo is assumed to be representative of further laxative treatment, placebo was costed in our revised analysis as the simple average of all standard laxative treatments (including bulk-forming laxatives, stimulant laxatives and osmotic laxatives), as per Table 72 of the evidence review group (ERG) report, with drug costs taken from the British National Formulary (BNF) \[[@CR31], [@CR32]\]. In the clinical trials for lubiprostone, patients could be given rescue medication if they had no SBM for 3 consecutive days. The proportions of patients receiving lubiprostone or placebo who required a bisacodyl (Dulcolax^®^) suppository as rescue medication were 30 and 39% in weeks 1--2 and 15 and 20% in weeks 3--4, respectively (see Table 1 in the Electronic Supplementary Material \[ESM\]). The proportion of prucalopride-treated patients requiring rescue medication was assumed to be the same as that for those receiving lubiprostone. A 12-pack of 10-mg Dulcolax^®^ suppositories costs £3.53 according to the BNF \[[@CR31]\].

The mean ingestion rate of lubiprostone for patients on treatment in the clinical trials was 83% (standard error 1.5%) \[[@CR33]\], so reduced dosing was considered for lubiprostone in the base case. For the scenarios focusing on comparison with prucalopride, full dosing of both lubiprostone and prucalopride was assumed as data on reduced dosing for prucalopride were not available. All treatments may be prescribed either in primary care by a GP or in secondary care during an outpatient appointment with a gastroenterologist \[[@CR32]\]. The base case in the economic model assumed it was equally likely (50:50 split) that these were initiated by a GP or a gastroenterologist. Assessment of the treatment continuation rule was assumed in the base case to be performed through a telephone consultation, 80% of which were assumed to be with a nurse and the remainder with a GP.

Medical resource use was defined by whether a patient was receiving active treatment and whether their constipation was resolved or unresolved. Another study in constipation reported the frequency of accident and emergency visits, hospital outpatient visits, laboratory tests and GP contact for patients receiving Macrogol 4000 and lactulose over 3 months \[[@CR34]\]. Resource use was reported separately for monotherapy and combination therapy, for patients who remained on initial therapy, switched therapy or discontinued therapy. It was assumed that patients on initial therapy represented those on initial therapy in our model, those who switched therapy represented those whose CIC was unresolved, and those who discontinued therapy were resolved, averaging Macrogol 4000 and lactulose. The costs of resources were taken from NHS Reference Costs 2015--16 \[[@CR35]\] and Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care 2016 \[[@CR36]\]. Costs for referral to investigations and invasive procedures were taken from the NICE assessment of prucalopride, updated to year 2016 values \[[@CR15]\]. Table [2](#Tab2){ref-type="table"} shows the costs and utilities.

Model Validation {#Sec8}
----------------

Before the model was submitted to NICE, a senior health economist with no involvement in the project verified and critiqued the model according to a checklist to determine whether the calculations were appropriate and correct. Subsequently, as part of the NICE process, the model was verified and critiqued by an independent academic centre and discussed by an expert committee to validate the structure, assumptions and inputs \[[@CR37]\].

Analysis {#Sec9}
--------

The base-case analysis presented here makes three changes to the scenario considered by NICE. First, the cost of placebo treatment was included to reflect the costs of laxative treatment, and immediate referral was added as a comparator. Second, the costs were updated by using 2016 sources. Third, the time horizon was extended to 10 years to ensure patients receiving immediate referral were in health states comparable to those receiving lubiprostone, prucalopride or placebo at the end of the model.

Deterministic and probabilistic analyses were performed for the base-case analysis. Probabilistic sensitivity analysis was conducted by simultaneously sampling each parameter from its probability distribution and calculating the total costs and QALYs for each arm. This was done 1000 times (as the result stabilised by this point), and the mean total costs and QALYs for each arm from the 1000 simulations were used to calculate incremental results. Distributions for cost, resource use and utilities are shown in Table 1 in the ESM. Response to placebo was sampled from a beta distribution with alpha equal to the number of responders and beta the number of non-responders. Relative risks for lubiprostone versus placebo and for prucalopride versus lubiprostone were sampled from log-Normal distributions. Discontinuation parameters were sampled from a multivariate Normal distribution. For the base case, the probability that each treatment is the most cost effective at a threshold of £20,000 per QALY was calculated (the lower end of the suggested NICE 'threshold' for determining a cost-effective medicine) \[[@CR17]\]. This analysis was performed to capture parameter uncertainty.

One-way deterministic sensitivity analysis was conducted by setting each parameter in turn to the lower and then upper bound of its 95% confidence interval. This analysis was performed to explore the key drivers of the cost-effectiveness results.

Scenario analyses were performed for the six other indirect comparisons possible between lubiprostone and prucalopride (in addition to testing the assumption of equal efficacy). A scenario where CIC influenced mortality was considered, as was a scenario where placebo had no lasting effect beyond 2 weeks. These scenarios explored the structural uncertainty associated with model assumptions.

Results {#Sec10}
=======

Patient Flow {#Sec11}
------------

After the initial treatment period, 69.3 and 61.5% of patients were eligible to continue treatment with lubiprostone or prucalopride, respectively. After 1 year, 8.1% of patients remained on lubiprostone, 8.1% on prucalopride, and 6.0% on placebo. After 10 years, all patients had discontinued lubiprostone, prucalopride or placebo. Figure [2](#Fig2){ref-type="fig"} shows the proportion of patients in each health state over the time horizon for each treatment.Fig. 2Patient flow

Base-Case Results {#Sec12}
-----------------

Table [3](#Tab3){ref-type="table"} presents the results of the deterministic analysis considered by NICE and the stepwise changes to meet the (deterministic and probabilistic) base case for this analysis. The base-case deterministic results show that immediate referral is both the least costly and the least effective option. Placebo (representing standard care) is more expensive and generates more QALYs, with a resulting incremental cost-effectiveness ratio (ICER) of £9909/QALY. Lubiprostone is more expensive and more effective than placebo and immediate referral as patients spend longer on treatment, generating both costs and QALYs. Lubiprostone has an ICER of £58,979 compared with placebo or £21,152 compared with immediate referral. This means that lubiprostone is not cost effective compared with placebo but is cost effective compared with immediate referral at a threshold of £30,000/QALY. Prucalopride is more costly than lubiprostone, primarily because the drug costs are higher, but less effective than lubiprostone based on the results of the indirect comparison and patients spending less time on treatment due to this lower efficacy. Prucalopride is therefore dominated by lubiprostone.Table 3Base-case economic model resultsVariablesTotalIncrementalICER (£)ICER vs. baseline (£)Costs (£)LYsQALYsCosts (£)LYsQALYsNICE analysis Placebo15060.99580.8619 Lubiprostone16720.99580.86451650.00000.002664,46464,464 Prucalopride17130.99580.8643410.0000− 0.0002Dominated87,085NICE analysis, with placebo cost, and immediate referral added Immediate referral14550.99580.8532 Placebo15220.99580.8619670.00000.00977567756 Lubiprostone16720.99580.86451490.00000.00358,25619,279 Prucalopride17130.99580.8643410.00000.000Dominated23,358NICE analysis, with placebo cost, and immediate referral added, year 2016 values Immediate referral15270.99580.8532 Placebo15730.99580.8619460.000.00952875287 Lubiprostone17170.99580.86451450.000.00356,54916,984 Prucalopride17590.99580.8643420.000.000Dominated21,084Base-case: deterministic analysis\
NICE analysis, with placebo cost, immediate referral added, and 10-year time horizon Immediate referral47558.53248.4812 Placebo48898.53248.49471340.000.01499099909 Lubiprostone51268.53248.49872370.000.00458,97921,152 Prucalopride51958.53248.4985690.000.000Dominated25,324Base case: probabilistic analysis Immediate referral47448.53088.4808 Placebo48798.53088.49451350.00000.0136986921,129 Lubiprostone51188.53088.49862400.00000.004158,79558,795 Prucalopride51928.53088.4986740.00000.0001777,05375,178*ICER* incremental cost-effectiveness ratio, *LYs* life-years, *NICE* UK National Institute for Health and Care Excellence, *QALYs* quality-adjusted life-years

Sensitivity Analyses {#Sec13}
--------------------

### Probabilistic Sensitivity Analyses {#Sec14}

Table [3](#Tab3){ref-type="table"} contains probabilistic base-case results, and Fig. [3](#Fig3){ref-type="fig"} shows a cost-effectiveness acceptability curve for the four options. At a willingness to pay below approximately £10,000 per QALY, the most cost-effective option is immediate referral. As willingness to pay increases, lubiprostone and prucalopride become more attractive options. At around £40,000--50,000/QALY, prucalopride has a higher probability of being cost effective than lubiprostone as, in some simulations, prucalopride is more effective than lubiprostone and has a lower ICER compared with placebo than does lubiprostone. Conversely, in the scenarios where lubiprostone is more effective than prucalopride, the ICERs for both prucalopride and lubiprostone versus placebo are above £50,000, so placebo is the most cost-effective treatment. At around £60,000/QALY, lubiprostone has a higher probability of being cost effective than placebo. As the willingness to pay increases, both lubiprostone and prucalopride increase in probability of being the optimum treatment; however, both rise in tandem because of the uncertainty in the relative efficacy.Fig. 3Cost-effectiveness acceptability curve

### Deterministic Sensitivity Analyses {#Sec15}

Figure [4](#Fig4){ref-type="fig"} shows the tornado diagrams for the comparison between lubiprostone and placebo and between lubiprostone and prucalopride. These two comparisons are presented as they represent the decision problem considered by NICE. The comparison between lubiprostone and placebo used base-case settings. The net benefit of lubiprostone compared with placebo using a threshold of £20,000 (incremental QALYs × £20,000 threshold − incremental costs) was always negative, showing that, even at the upper and lower bounds of each parameter, lubiprostone was not cost effective compared with placebo.Fig. 4Tornado diagram using 95% confidence interval of parameters: **a** lubiprostone vs. placebo and **b** lubiprostone vs. prucalopride. *GP* general practitioner, *ITT* intention to treat, *QALYs* quality-adjusted life-years, *SBM* spontaneous bowel movement

The biggest drivers were the response rate for placebo, proportion of patients cured by biofeedback and the utility value for responders. When more placebo-treated patients responded, the response rate for lubiprostone also increased and the costs and QALYs for both arms increased---but the relative increase in costs was greater for lubiprostone, so the ICER increased. When the effectiveness of biofeedback increased, biofeedback became more cost effective---since more placebo-treated patients underwent biofeedback, the cost effectiveness of placebo increased. When the utility value for responders increased, the quality-of-life benefit of lubiprostone increased, leading to an increase in the net benefit of lubiprostone.

The comparison between lubiprostone and prucalopride used base-case settings but an ingestion rate of 100% for lubiprostone. The net benefit of lubiprostone using a threshold of £20,000 was always positive---showing that, even at the upper and lower bounds of each parameter, lubiprostone was cost effective compared with prucalopride. The biggest drivers were the proportion having a GP visit (rather than a consultation with a gastroenterologist) to prescribe each drug, and the relative efficacy of lubiprostone and prucalopride. It is unsurprising that one drug would become more cost effective than the other if it could be prescribed in primary rather than secondary care whereas the other could not. The impact of relative efficacy was explored in scenario analyses.

### Scenario Analyses {#Sec16}

We conducted deterministic and probabilistic scenario analyses varying the relative effectiveness of lubiprostone and prucalopride using different outcomes from the indirect comparison. In all cases, the incremental net benefit at £20,000/QALY was positive for lubiprostone. Even where prucalopride was more effective than lubiprostone, it was not cost effective compared with lubiprostone as the additional cost resulting from the higher treatment cost and longer duration was not sufficiently outweighed by the QALYs gained at standard willingness-to-pay thresholds.

In an analysis using a different source of utilities \[[@CR34]\], the difference between responder and non-responder was greater, so the ICER for lubiprostone versus placebo decreased to £49,802/QALY (as lubiprostone provided more time in a responder health state).

In a scenario including increased mortality for unresolved CIC, the absolute life-years and QALYs for each treatment decreased. However, since there was a mortality benefit to remaining on treatment, the incremental QALYs for placebo versus immediate referral and lubiprostone versus placebo increased slightly, so both ICERs decreased (£9599 for placebo vs. immediate referral, and £20,592 for lubiprostone vs. placebo). Prucalopride continued to be dominated by lubiprostone.

We considered an extreme scenario where the effect of placebo treatment was limited to 2 weeks. In this case, the ICER for placebo versus immediate referral increased to £77,959/QALY and the ICER for lubiprostone versus placebo decreased to £17,926/QALY because the benefit of placebo was much reduced. However, the long-term efficacy of placebo is currently unknown.

Discussion {#Sec17}
==========

This analysis showed that, at a willingness to pay of £20,000--30,000/QALY, placebo was the most cost-effective treatment. Lubiprostone was cost effective compared with immediate referral and dominated prucalopride but was not cost effective compared with placebo in the base case. NICE recommended lubiprostone on the grounds that it was at least as effective as prucalopride and has a slightly lower acquisition cost but noted that evidence is insufficient to demonstrate it is cost effective compared with placebo.

The major source of uncertainty in determining whether lubiprostone represents value for money therefore is in understanding the treatment pathway without lubiprostone. This appears to be driven by the lack of clear guidelines for the treatment of patients despite the condition being relatively common. If lubiprostone is positioned as a treatment for people for whom at least two previous laxatives have failed and in whom invasive procedures are being considered, assuming patients would receive standard laxatives (represented by placebo) may not be appropriate. This would indicate the most appropriate comparison is versus immediate referral. For these patients, lubiprostone avoids or delays referrals to investigations and invasive procedures, partially offsetting the costs of the drug, with patient quality of life improved (as shown by the QALY gain).

The comparison against prucalopride demonstrated that lubiprostone was cost effective in all scenarios. Although it was not possible to conduct analyses using the same endpoint that was used to model response to lubiprostone and placebo, it was possible to conduct indirect comparisons on seven different endpoints across a range of efficacy outcomes. Whilst lubiprostone appeared more effective in most, this rarely reached statistical significance, leading to uncertainty as to whether prucalopride or lubiprostone is the more effective treatment. In scenario analysis where prucalopride was assumed to be more effective than lubiprostone, whilst prucalopride generated more QALYs, lubiprostone remained cost effective because of lower costs. A recent network meta-analysis in CIC included lubiprostone and prucalopride, with change in SBM as the outcome. Although the numerical results of this network meta-analysis were not identical to our analysis (due to differences in methods and included studies), the study found the two drugs to be equally effective, similar to the conclusions of our analyses \[[@CR38]\]. When both are equally effective, lubiprostone is cost saving because of lower drug costs. However, it should be noted that these results may not apply in a subgroup of elderly patients, where the dose and hence cost of prucalopride is lower. We were unable to estimate the relative cost effectiveness of lubiprostone and prucalopride in this specific population as we did not have data for the effectiveness of both treatments in this subgroup alone. It would not be appropriate to assume the same effectiveness as the base case because effectiveness may differ in the elderly population, particularly when considering a reduced dose of prucalopride.

This is the first study to consider the cost effectiveness of lubiprostone in the treatment of CIC in the UK, though an economic evaluation was performed for prucalopride in this indication as part of a previous NICE appraisal \[[@CR18]\]. The results of the previous economic model showed prucalopride to have an ICER of £16,000 compared with placebo, which is lower than the ICER for this comparison from our model (£79,670). This difference appears to be mainly due to different model structures and time horizons. We consider our model to be more accurate, as it reflects the treatment pathway after failure of the initial treatment and over a much longer time horizon, after which patients will be in the same health states, and thus consequences from treatment were appropriately costed. A targeted literature search identified four other economic evaluations in chronic constipation. One study looked at the cost effectiveness of prucalopride in the Netherlands; this economic evaluation used the same model structure, comparators and assumptions as the aforementioned previous NICE appraisal but used costs relevant to Dutch payers and considered a longer time horizon \[[@CR39]\]. Huang et al. \[[@CR40]\] developed a decision tree model comparing linaclotide with lubiprostone in the USA. Response to therapy was defined as (1) having one of the best two satisfaction answers of a 5-point global treatment satisfaction scale at week 4 or (2) having a weekly SBM frequency ≥ 4 at week 4. The time horizon used was 4 weeks, and results showed both treatments resulted in equal QALYs, so only a cost comparison was made. Linaclotide is not licensed in the UK so was not included in our model. Taylor et al. \[[@CR41]\] and Guest et al. \[[@CR34]\] compared Macrogol 3350 and Macrogol 4000 to lactulose, respectively. Both studies used a decision tree model with timelines of 3 and 6 months.

In the appraisal of lubiprostone, the NICE appraisal committee concluded the model structure was valid for the decision problem, on account of it considering treatment stopping rules, discontinuation and referral to secondary care. The committee reviewed the data sources and assumptions and found them to be appropriate \[[@CR32]\]. This process, together with the critique of the model by an independent economist, and verification of the model calculations by an independent review group, addresses some of the best practices recommended for model validation \[[@CR42]\]. An important part of validation that we were unable to address involves comparing predicted results with those observed in longitudinal studies. We used the long-term published lubiprostone studies as data sources in the model, so could not then validate against them. We could not identify any additional long-term follow-up studies conducted since we developed the model. This is not surprising, given there was no requirement from reimbursement or licensing agencies to collect additional data. Routine collection of long-term data would facilitate validation of future modelling studies in functional bowel disorders.

Some limitations to the model are linked to the data available. Most notable here are the assumptions around the extrapolation of efficacy and discontinuation data beyond the relatively short clinical trials (48 weeks for the open-label studies \[[@CR12]\]), despite the chronic nature of the condition. Despite the limitations of the data, sensitivity analyses demonstrated that the results of the model were robust to different data sources and assumptions, with lubiprostone being cost effective compared with prucalopride in all scenarios, and not cost effective compared with placebo except in extreme scenarios.

In conclusion, lubiprostone has been shown to be a cost-effective treatment compared with prucalopride or immediate referral in CIC but not compared with placebo. The implementation of the guidance issued by NICE \[[@CR32]\] should increase the quality of life for patients with CIC for whom previous treatments have failed, should provide a further treatment option, and may save NHS resources depending on the comparator displaced in practice---either in avoiding unnecessary tests or, more likely, in displacing prucalopride, which has a higher acquisition cost. As the number of health technology appraisals in this area increases, we hope this leads to the provision of further evidence-based guidelines in the area and clarification on the most appropriate treatment pathway.
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